Ipamorelin (5MG)

Selective GH Release:

Ipamorelin promotes dose-dependent GH secretion without the broad endocrine activation seen with some GHRPs [2][3].

Specificity:

Exhibits minimal effect on ACTH, prolactin, and cortisol, allowing for selective GH-axis studies [2].

Pharmacokinetics:

Human PK studies show a terminal half-life of ~2 hours and GH peak around 0.7 hours post-infusion [3][5].

Metabolic & Regenerative Insights:

Research indicates benefits for cellular regeneration and anabolic pathways in controlled studies [6].

Citations

1. PubChem Compound Summary for Ipamorelin (CID 9831659): sequence Aib–His–D‑2Nal–D‑Phe–Lys–NH₂; molecular data.
2. Moulin A, Ryan J, Martinez J, Fehrentz JA. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552–560.
3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. “Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers.” Pharm Res. 1999;16(9):1412–1418.
4. PubChem data confirms the pentapeptide sequence and structural modifications.
5. Agersø H, et al. “Pharmacokinetics and pharmacodynamics of ipamorelin, a new GH secretagogue, in humans.” Br J Clin Pharmacol. 2001;52(3):273–279.
6. Peptides.guide – Ipamorelin research summary, metabolic and regenerative effects.